Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB Clinical Trial on Adjuvant Low-dose Ipilimumab Plus Nivolumab Following the Resection of Melanoma Macrometastases

Next Previous
Trial Profile

A Phase IB Clinical Trial on Adjuvant Low-dose Ipilimumab Plus Nivolumab Following the Resection of Melanoma Macrometastases

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions

    • Most Recent Events

    • 21 Sep 2020 Results assessing C-reactive protein as biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting using pooled data from (NCT02941744, and an observational study) presented at the 45th European Society for Medical Oncology Congress
    • 04 Jun 2019 According to results presented at the 55th Annual Meeting of the American Society of Clinical Oncology, secondary endpoints for this trial included safety, distant metastasis-free survival (DMFS) and overall survival (OS).
    • 04 Jun 2019 According to results presented at the 55th Annual Meeting of the American Society of Clinical Oncology, recruitment to Cohort-B was closed prematurely following registration of nivolumab in the adjuvant setting by EMA.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top